Invest
27 Years
4.4 Star
1 Crore +
Pharmaceuticals firm Dishman Carbogen Amcis announced Q1FY23 Result :
- Net Revenue at Rs 5,406.1 mn in Q1 FY23 down by 1.8% YoY mainly on account of lower revenues from Netherlands business.
- Dishman Carbogen Amcis - NCE APIs and Intermediates revenue increased by 91.9% YoY primarily due to:
- Increased supplies of APIs and intermediates from Bavla site driven by successful customer audits.
- Dishman Carbogen Amcis - Quats and Generics revenue increased by 7.1% YoY primarily due to:
- Increased demand for these products especially in the exports market driven by exceptional operational performance by Naroda site.
- Carbogen Amcis - CRAMS revenue increased by 3.0% YoY primarily due to:
- Higher Development revenue comprising 70% of the total revenue for the quarter.
- Carbogen Amcis - Cholesterol and Vitamin D analogues revenue decreased by 46.0% YoY primarily due to:
- Carbogen Amcis BV’s Q1FY22 revenue was almost 38% of the total year’s revenue, thus extremely front ended, which is not the case this year. One of the customers last year had stocked up huge amount of inventory in June quarter.
- EBITDA Margin at 16.3% in Q1 FY23 compared to 18.3% in Q1 FY22 due to:
- Higher energy costs and higher raw material costs impacted the cost base significantly in Carbogen Amcis BV in the first quarter as compared to last year same quarter.
- Higher logistics costs has also impacted the cost base globally.
- One time FX loss impact approximately Rs. 9.00 crores as part of “Other Expenses”
FAQ’s on Dishman Carbogen Amcis Ltd Shares
